Cover Image
Market Research Report

Global Autoimmune Drugs Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 354855
Published Content info 124 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Autoimmune Drugs Market 2018-2022
Published: December 14, 2018 Content info: 124 Pages
Description

About this market

High cost of autoimmune drugs to drive market growth. Governments and regulatory bodies have undertaken several initiatives to reduce the costs of therapies for autoimmune disorders mainly rheumatoid arthritis. Despite these efforts, autoimmune drugs continue to remain expensive. Biologics and biosimilars are expensive when compared with conventional therapies such as NSAIDs. Technavio' s analysts have predicted that the autoimmune drugs market will register a CAGR of more than 8% by 2022.

Market Overview

Targeted therapeutic mechanism of biologics

By providing a targeted action, biologics tend to be more effective and have lesser side effects compared with small molecule agents. Hence, the introduction of biologic therapy to manage autoimmune disorders is driving the market at a very rapid pace.

Reimbursement challenges of autoimmune drugs

The insurers are reluctant to provide reimbursement for the drugs for treatment of autoimmune diseases due to the lack of knowledge; therefore, they generally do not provide any provisions for the reimbursement of drugs for rheumatoid arthritis and other autoimmune diseases.

For the detailed list of factors that will drive and challenge the growth of the autoimmune drugs market during the 2018-2022, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Techman-Head Group and Brackett Aircraft Company the competitive environment is quite intense. Factors such as the targeted therapeutic mechanism of biologics and the high cost of autoimmune drugs, will provide considerable growth opportunities to autoimmune drugs manufactures. AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR21800

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY THERAPY AREA

  • Segmentation by therapy area
  • Comparison by therapy area
  • Rheumatoid arthritis - Market size and forecast 2017-2022
  • Multiple sclerosis - Market size and forecast 2017-2022
  • Psoriasis - Market size and forecast 2017-2022
  • Inflammatory bowel disease - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by therapy area

PART 09: MARKET SEGMENTATION BY TYPE OF MOLECULE

  • Segmentation by type of molecule
  • Biologics
  • Small molecules

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • UCB

PART 17: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: mAbs and biologics for autoimmune diseases
  • Exhibit 06: Small molecules for autoimmune diseases
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2017
  • Exhibit 09: Validation techniques employed for market sizing 2017
  • Exhibit 10: Global - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 11: Biosimilars approved in 2017
  • Exhibit 12: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 13: Five forces analysis 2017
  • Exhibit 14: Five forces analysis 2022
  • Exhibit 15: Bargaining power of buyers
  • Exhibit 16: Bargaining power of suppliers
  • Exhibit 17: Threat of new entrants
  • Exhibit 18: Threat of substitutes
  • Exhibit 19: Threat of rivalry
  • Exhibit 20: Market condition - Five forces 2017
  • Exhibit 21: Therapy area - Market share 2017-2022 (%)
  • Exhibit 22: Comparison by therapy area
  • Exhibit 23: Rheumatoid arthritis - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 24: Rheumatoid arthritis - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Multiple sclerosis - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 26: Multiple sclerosis - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Psoriasis - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 28: Psoriasis - Year over year growth 2018-2022 (%)
  • Exhibit 29: Inflammatory bowel disease - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 30: Inflammatory bowel disease - Year-over-year growth 2018-2022 (%)
  • Exhibit 31: Others - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 32: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 33: Market opportunity by therapy area
  • Exhibit 34: Customer landscape
  • Exhibit 35: Global - Market share by geography 2017-2022 (%)
  • Exhibit 36: Regional comparison
  • Exhibit 37: Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 38: Molecules in the pipeline for autoimmune disorders in the Americas
  • Exhibit 39: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 40: Top 3 countries in Americas
  • Exhibit 41: EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 42: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 43: Top 3 countries in EMEA
  • Exhibit 44: APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 45: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 46: Top 3 countries in APAC
  • Exhibit 47: Market opportunity
  • Exhibit 48: Sales of major autoimmune drugs
  • Exhibit 49: Patent expiration dates for some of the biologics
  • Exhibit 50: Vendor landscape
  • Exhibit 51: Landscape disruption
  • Exhibit 52: Vendors covered
  • Exhibit 53: Vendor classification
  • Exhibit 54: Market positioning of vendors
  • Exhibit 55: AbbVie overview
  • Exhibit 56: AbbVie - Business segments
  • Exhibit 57: AbbVie - Organizational developments
  • Exhibit 58: AbbVie - Geographic focus
  • Exhibit 59: AbbVie - Key offerings
  • Exhibit 60: Amgen overview
  • Exhibit 61: Amgen - Business segments
  • Exhibit 62: Amgen - Organizational developments
  • Exhibit 63: Amgen - Geographic focus
  • Exhibit 64: Amgen - Key offerings
  • Exhibit 65: Johnson & Johnson overview
  • Exhibit 66: Johnson & Johnson - Business segments
  • Exhibit 67: Johnson & Johnson - Organizational developments
  • Exhibit 68: Johnson & Johnson - Geographic focus
  • Exhibit 69: Johnson & Johnson - Segment focus
  • Exhibit 70: Johnson & Johnson - Key offerings
  • Exhibit 71: Novartis overview
  • Exhibit 72: Novartis - Business segments
  • Exhibit 73: Novartis - Organizational developments
  • Exhibit 74: Novartis - Geographic focus
  • Exhibit 75: Novartis - Segment focus
  • Exhibit 76: Novartis - Key offerings
  • Exhibit 77: Pfizer overview
  • Exhibit 78: Pfizer - Business segments
  • Exhibit 79: Pfizer - Organizational developments
  • Exhibit 80: Pfizer - Geographic focus
  • Exhibit 81: Pfizer - Segment focus
  • Exhibit 82: Pfizer - Key offerings
  • Exhibit 83: UCB overview
  • Exhibit 84: UCB - Business segments
  • Exhibit 85: UCB - Organizational developments
  • Exhibit 86: UCB - Geographic focus
  • Exhibit 87: UCB - Segment focus
  • Exhibit 88: UCB - Key offerings
Back to Top